| Literature DB >> 26923776 |
Li Zhou1,2, Kui Wang1, Qifu Li2, Edouard C Nice1,3, Haiyuan Zhang2, Canhua Huang1,2.
Abstract
Cancer is a common disease that is a leading cause of death worldwide. Currently, early detection and novel therapeutic strategies are urgently needed for more effective management of cancer. Importantly, protein profiling using clinical proteomic strategies, with spectacular sensitivity and precision, offer excellent promise for the identification of potential biomarkers that would direct the development of targeted therapeutic anticancer drugs for precision medicine. In particular, clinical sample sources, including tumor tissues and body fluids (blood, feces, urine and saliva), have been widely investigated using modern high-throughput mass spectrometry-based proteomic approaches combined with bioinformatic analysis, to pursue the possibilities of precision medicine for targeted cancer therapy. Discussed in this review are the current advantages and limitations of clinical proteomics, the available strategies of clinical proteomics for the management of precision medicine, as well as the challenges and future perspectives of clinical proteomics-driven precision medicine for targeted cancer therapy.Entities:
Keywords: Clinical proteomics; cancer therapy; drug target identification; mass spectrometry; precision medicine
Mesh：
Substances：
Year: 2016 PMID： 26923776 DOI： 10.1586/14789450.2016.1159959
Source DB: PubMed Journal: Expert Rev Proteomics ISSN： 1478-9450 Impact factor: 3.940